DICLOFENAC: AN UPDATE ON ITS MECHANISM OF ACTION AND SAFETY PROFILE
Main Article Content
Keywords
diclofenac, mechanism action, safety, NSAID, cyclooxygenase.
Abstract
Diclofenac is a widely used nonsteroidal anti-inflammatory drug ( NSAID) known for its effectiveness in managing pain and inflammation. It functions by inhibiting the enzyme cyclooxygenase, thereby reducing the production of inflammatory mediators. This essay provides an update on the mechanism of action and safety profile of diclofenac, highlighting recent research findings. The method involved an extensive review of the literature on diclofenac, focusing on its mechanism of action and safety considerations. The results indicate that diclofenac exerts its anti-inflammatory effects primarily by inhibiting the production of prostaglandins, while also possessing other of action. The safety profile of diclofenac has been the subject of ongoing debate due its potential cardiovascular gastrointestinal risks. Overall, this essay aims to enhance understanding of diclofenac's pharmacology and safety considerations
References
2. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382(9894):769-79.
3. Shah SS, Ohlstein EH, Hauser KL, DeYoung M. Characterization of the in vivo cyclooxygenase-inhibitory properties of nonsteroidal anti-inflammatory drugs. Adv Prostaglandin Thromboxane Leukot Res. 1986; 16:37-44.
4. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008; 118(18):1894-909.
5. Brune K, Hinz B. The discovery and development of anti-inflammatory drugs. Pharmacol Ther. 2004; 102(2):131-61.
6. Rostom A, Dubé C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007; 146(5):376-89.
7. Rainsford KD. Fifty years of ibuprofen. Int J Clin Pract Suppl. 2013; 178:2-4.
8. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000; 343(21):1520-8.
9. Hawkey CJ. COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol. 2001; 15(5):801-20.
10. Goldstein JL, Chan FK, Lanza FL, et al. Haemoglobin decreases in NSAID users over time: a comparison between pre-selective and selective inhibitors. Aliment Pharmacol Ther. 2003; 18(5):485-9.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Mishari Mohammed Dhafer Al-Otaibi
Pharmacy, King Khalid Hospital in Al Kharj
Eid Ghazy Hamdan Alotaibi
Pharmacy, The first health cluster in Riyadh
Bander Mohammad Ali Al.Masoud
pharmaceutical, Al hareeq general Hospital
Adel Saeed Saleh Al-Wadaei
pharmacy technician, Prince Salman bin Mohammed Hospital in Dalam
Abdullah Qabl Khuwaytim Almutairi
Pharmacist Assistant, Hotat Bani Tamim General Hospital
Mohammed Badr Mubarak Alotaibi
Pharmacy Technician, Shaqra general hospital